ProCE Banner Activity

Recurrent Hyperkalemia in Heart Failure

Clinical Thought

Here are my thoughts on the reason for and management of recurrent hyperkalemia in heart failure and why dose de-escalation or RAAS inhibitor discontinuation to prevent hyperkalemia does a disservice to our patients. The incorporation of potassium binders into clinical practice can help alleviate recurrent hyperkalemia burden.

Released: December 06, 2023

Share

Faculty

Ileana L. Piña

Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA

Professor of Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA

Professor of Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania

Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA: consultant/advisor/speaker: Boehringer Ingelheim.